Advanced Therapeutics最新文献

筛选
英文 中文
Issue Information (Adv. Therap. 10/2025) 发布信息(ad . therapy . 10/2025)
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-10-14 DOI: 10.1002/adtp.70063
{"title":"Issue Information (Adv. Therap. 10/2025)","authors":"","doi":"10.1002/adtp.70063","DOIUrl":"https://doi.org/10.1002/adtp.70063","url":null,"abstract":"<p>Cover image provided courtesy of Yongheng Zhu, Xinghua Gao, Yuan Zhang, and co-workers.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Viral Manufacturing of Cellular Immunotherapy Using Simple Mechanical Transfection Device (Adv. Therap. 10/2025) 使用简单机械转染装置非病毒制造细胞免疫疗法(ad . therapp . 10/2025)
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-10-14 DOI: 10.1002/adtp.70061
Yerim Lee, Wanling Wong, Theresa Seah, Dionis Yew, Cyrus W. Beh
{"title":"Non-Viral Manufacturing of Cellular Immunotherapy Using Simple Mechanical Transfection Device (Adv. Therap. 10/2025)","authors":"Yerim Lee,&nbsp;Wanling Wong,&nbsp;Theresa Seah,&nbsp;Dionis Yew,&nbsp;Cyrus W. Beh","doi":"10.1002/adtp.70061","DOIUrl":"https://doi.org/10.1002/adtp.70061","url":null,"abstract":"<p>T-cells forced through micro-sized pores become permeable, letting Chimeric Antigen Receptor (CAR) mRNA enter. The cells then express CAR proteins, gaining potent cancer-killing function. This method offers a path toward efficient, reproducible manufacturing and reduced therapy costs for patients. More details can be found in the Research Article by Cyrus W. Beh and co-workers (DOI: 2500094). Cover image by Ahmad Amirul Abdul Rahim.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma (Adv. Therap. 9/2025) 白蛋白结合紫杉醇联合抗pd -1抗体治疗胰管腺癌的疗效和安全性(Adv. Therap. 9/2025)
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-18 DOI: 10.1002/adtp.70054
Wenjing Hao, Yunxia Wang, Jun Zhang, Weimin Cai
{"title":"Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma (Adv. Therap. 9/2025)","authors":"Wenjing Hao,&nbsp;Yunxia Wang,&nbsp;Jun Zhang,&nbsp;Weimin Cai","doi":"10.1002/adtp.70054","DOIUrl":"10.1002/adtp.70054","url":null,"abstract":"<p>The cover image shows a vivid dichotomy between two therapeutic landscapes. On the left, a harmonious and flourishing tumor microenvironment under combination therapy is brought to life—swallows in flight and radiant light symbolize the synergy of immune cells and cytokines. In stark contrast, the right side unveils the turmoil of PD-1 monotherapy: splattered ink evokes uncontrolled tumor growth, gnarled branches allude to immune-related adverse events, and dark birds take wing as harbingers of excessive immune infiltration—together conjuring a bleak, unsettling scene. More details can be found in the Research Article by Weimin Cai and co-workers (DOI: 2500075).\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 9","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Issue Information (Adv. Therap. 9/2025) 发布信息(第9/2025号公告)
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-18 DOI: 10.1002/adtp.70052
{"title":"Issue Information (Adv. Therap. 9/2025)","authors":"","doi":"10.1002/adtp.70052","DOIUrl":"10.1002/adtp.70052","url":null,"abstract":"<p>Cover image provided courtesy of Yongheng Zhu, Xinghua Gao, Yuan Zhang, and co-workers.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 9","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnologies Targeting Traumatic Brain Injury: From Diagnosis to Targeted Therapy 纳米技术靶向创伤性脑损伤:从诊断到靶向治疗
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-12 DOI: 10.1002/adtp.202500402
Kunyao Xu, Yijia Zhang, Qiong Dai, Chaoyong Liu, Yunfeng Lu
{"title":"Nanotechnologies Targeting Traumatic Brain Injury: From Diagnosis to Targeted Therapy","authors":"Kunyao Xu,&nbsp;Yijia Zhang,&nbsp;Qiong Dai,&nbsp;Chaoyong Liu,&nbsp;Yunfeng Lu","doi":"10.1002/adtp.202500402","DOIUrl":"https://doi.org/10.1002/adtp.202500402","url":null,"abstract":"<p>Traumatic brain injury (TBI) is a complex neurological condition involving both primary mechanical damage and a cascade of secondary injuries, such as oxidative stress, neuroinflammation, and disruption of the blood-brain barrier (BBB). Although significant progress has been made in understanding TBI pathophysiology, current treatment strategies remain largely supportive and fail to effectively target the underlying secondary injury mechanisms. This therapeutic gap highlights the urgent need for innovative and more effective interventions. Nanotechnology has emerged as a promising avenue, offering targeted drug delivery systems, improved BBB penetration, and integrated diagnostic and therapeutic capabilities. These innovations have the potential to significantly enhance treatment precision and outcomes in TBI. This review provides a systematic overview of the pathological processes underlying TBI, critically assesses the limitations of existing therapeutic approaches, and summarizes recent advances in nanomedicine-based strategies developed over the past five years. Particular emphasis is placed on emerging diagnostic technologies and therapeutic innovations, offering perspectives on future directions for TBI research and clinical translation.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Design to Outcome: The Role of Bi- and Multifunctional Ligands in Modern Therapeutics 从设计到结果:双功能和多功能配体在现代治疗中的作用
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-12 DOI: 10.1002/adtp.202500146
Célia Bouacha, Séverine Denoyelle, Sonia Cantel
{"title":"From Design to Outcome: The Role of Bi- and Multifunctional Ligands in Modern Therapeutics","authors":"Célia Bouacha,&nbsp;Séverine Denoyelle,&nbsp;Sonia Cantel","doi":"10.1002/adtp.202500146","DOIUrl":"https://doi.org/10.1002/adtp.202500146","url":null,"abstract":"<p>The multifunctional strategy offers significant benefits in developing highly selective targeting biomolecules for therapeutics, diagnostics, dynamics studies, or mapping processes in various environments. Bioorthogonal reactions constitute an engineering approach enabling the attachment of ligands targeting receptors involved in numerous physiological dysfunctions onto multifunctional scaffolds. Herein, the latest generation of derivatized probes are overviewed for high-resolution screening in diagnosis or treatment. These compounds also represent valuable tools for investigating physiological roles, filling the gap of information in the mechanism of understanding various receptors and contributing to the design of effective drugs. Strategic linker design enhances ligand properties when developing dual-modality probes, impacting their effectiveness across applications. Nanoparticles are emerging as revolutionary concepts, offering promising solutions to address limitations in the field and paving the way for advanced therapeutic approaches and improved drug delivery systems.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silk-Derived Protein Molecular Weight Distribution Drives Differentiated Epithelial Cell Wound Closure and Substrate Adhesion Responses, In Vitro 丝源性蛋白分子量分布驱动分化上皮细胞伤口闭合和底物粘附反应
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-09 DOI: 10.1002/adtp.202500141
Ryan Schreiner, Waleed Abdel-Naby, David W. Infanger, Andres E. Perez Bay, Brigette Cole, Brian D. Lawrence
{"title":"Silk-Derived Protein Molecular Weight Distribution Drives Differentiated Epithelial Cell Wound Closure and Substrate Adhesion Responses, In Vitro","authors":"Ryan Schreiner,&nbsp;Waleed Abdel-Naby,&nbsp;David W. Infanger,&nbsp;Andres E. Perez Bay,&nbsp;Brigette Cole,&nbsp;Brian D. Lawrence","doi":"10.1002/adtp.202500141","DOIUrl":"https://doi.org/10.1002/adtp.202500141","url":null,"abstract":"<p>Silk-derived protein (SDP) is a fibroin hydrolysate that has been found to increase corneal epithelial cell migration rates in vitro and enhances corneal tissue regeneration in vivo, however, the mechanism of these bioactive effects is unclear. Previous work has shown that selecting specific molecular weight distributions (MWD) of the fibroin hydrolysate can impact its bioactivity. In this study, the effects of high (H<sup>−</sup>) and low molecular weight (L<sup>−</sup>) SDP fractions on human corneal limbal-epithelial cell viability, absorption, migration, attachment, and TGF-β signaling are characterized. Interestingly, L-SDP significantly increased cell migration and proliferation to accelerate wound closure rate, while the presence of TGFβRI inhibitor attenuated its activity. In contrast, H-SDP significantly decreased migration while increasing substrate adhesion, also down-regulating TGF-β mRNA levels. These findings demonstrate SDP's bioactivity can be tailored to govern cellular migration or adhesion by selecting a MWD which is optimal for a specific application.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing the Effectiveness of Chemotherapy in Osteosarcoma by Targeting Tumour-Associated Macrophages (TAMs) through STING Activation 通过STING激活靶向肿瘤相关巨噬细胞(tam)提高骨肉瘤化疗的有效性
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-05 DOI: 10.1002/adtp.202500167
Jordan C. O'Donoghue, Amanda Guitián-Caamaño, Maeve Boyce, Fiona E. Freeman
{"title":"Enhancing the Effectiveness of Chemotherapy in Osteosarcoma by Targeting Tumour-Associated Macrophages (TAMs) through STING Activation","authors":"Jordan C. O'Donoghue,&nbsp;Amanda Guitián-Caamaño,&nbsp;Maeve Boyce,&nbsp;Fiona E. Freeman","doi":"10.1002/adtp.202500167","DOIUrl":"https://doi.org/10.1002/adtp.202500167","url":null,"abstract":"<p>Osteosarcoma is an aggressive pediatric, adolescent, and young adult bone cancer with an immunosuppressive tumor microenvironment (TME) that limits immunotherapy efficacy. Tumor-associated macrophages, key players in immunosuppression and metastasis, are abundant in the osteosarcoma TME. The cGAS/STING pathway has emerged as a target for enhancing anti-tumor immunity. Here, this work investigates whether STING stimulation could reprogramme macrophages toward a tumoricidal M1-like phenotype and enhance doxorubicin efficacy against osteosarcoma. These results show that while doxorubicin induces cell death of osteosarcoma cells, it fails to activate STING in macrophages. However, pre-treatment of macrophages with a STING agonist enhances M1-like polarization of macrophages when indirectly co-cultured with chemotherapy-treated osteosarcoma cells, regardless of the original macrophage phenotype. Importantly, this work observes a loss of STING protein when cells are excessively stimulated with a STING agonist and sequential dosing offered no advantage over a single treatment. Finally, this work demonstrates that the combined therapy of doxorubicin and a single dose of neoadjuvant STING agonist synergistically increases osteosarcoma cell death via M1-macrophages compared to either therapy alone. These findings highlight the therapeutic potential of STING agonists to reprogram macrophages within the TME, and improve chemotherapy efficacy, offering a promising new strategy to enhance osteosarcoma treatment options.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Materials and Device Innovation: Choosing the Right and Relevant Biological Models 医用材料和器械创新:选择正确和相关的生物模型
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-05 DOI: 10.1002/adtp.202500096
Inge K. Herrmann, Tina Buerki-Thurnherr
{"title":"Medical Materials and Device Innovation: Choosing the Right and Relevant Biological Models","authors":"Inge K. Herrmann,&nbsp;Tina Buerki-Thurnherr","doi":"10.1002/adtp.202500096","DOIUrl":"https://doi.org/10.1002/adtp.202500096","url":null,"abstract":"<p>The success of medical devices and biomaterials hinges on selecting biological models that truly reflect human physiology and disease. A well-chosen model is not just a scientific necessity; it is a clinical imperative. Academic biomedical research often relies on readily accessible models that yield affordable, convenient, and predictable results. However, rodent models of sepsis, cancer, and cardiovascular disease frequently fail in clinical translation. Likewise, optimizing a device or material to fit a specific model (“overfitting”) can create false confidence, leading to expensive setbacks. While in vitro systems offer ethical advantages and mechanistic insights, they lack the complexity of living organisms. Animal models, though capable of capturing systemic effects, face species differences, ethical concerns, and poor clinical translation. Advances in 3D tissue engineering, organ-on-a-chip, and humanized models overcome many of these shortcomings, improving predictive accuracy and complementing animal models. Clinician involvement is crucial to aligning preclinical models with real-world medical needs. Moreover, unnecessary animal experiments should not be conducted or required without a clear translational route. Prioritizing clinically relevant models enhances patient safety, reduces research waste, and drives ethical, impactful medical innovation.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lycium Barbarum Polysaccharides Alleviate Hyperglycemia-Aggravated Cerebral Ischemia/Reperfusion Injury by Up-Regulating Wnt/β-Catenin Signaling 枸杞多糖通过上调Wnt/β-Catenin信号通路减轻高血糖加重的脑缺血再灌注损伤
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2025-09-04 DOI: 10.1002/adtp.202500045
Qi Zhao, Yu-Meng Jing, Li-Kun Zan, Jing Wang, Jie Wang, Li Jing, Yan-Feng Xi, Jian-Zhong Zhang
{"title":"Lycium Barbarum Polysaccharides Alleviate Hyperglycemia-Aggravated Cerebral Ischemia/Reperfusion Injury by Up-Regulating Wnt/β-Catenin Signaling","authors":"Qi Zhao,&nbsp;Yu-Meng Jing,&nbsp;Li-Kun Zan,&nbsp;Jing Wang,&nbsp;Jie Wang,&nbsp;Li Jing,&nbsp;Yan-Feng Xi,&nbsp;Jian-Zhong Zhang","doi":"10.1002/adtp.202500045","DOIUrl":"https://doi.org/10.1002/adtp.202500045","url":null,"abstract":"<p>Hyperglycemia aggravates neuronal damage in cerebral ischemia/reperfusion (I/R) injury. Emerging evidence indicates that <i>Lycium barbarum</i> polysaccharides (LBP) possess significant neuroprotective properties. However, the underlying mechanism by which LBP alleviates hyperglycemia-aggravated cerebral I/R injury remains unclear. This study aims to investigate the effects of LBP on hyperglycemia-aggravated cerebral I/R injury using in vivo and in vitro models. Rats are randomly assigned to the following groups: normoglycemic (NG), hyperglycemic (HG), and LBP-pretreated hyperglycemic (LBP) groups. Streptozotocin‑induced hyperglycemic rats undergo middle cerebral artery occlusion (MCAO) for 30 min, followed by reperfusion for 1, 3, and 7 days. Meanwhile, an in vitro model of hyperglycemia-aggravated cerebral I/R injury is established using murine hippocampal neuronal HT22 cells subjected to high glucose (HG) conditions combined with oxygen deprivation and reoxygenation (OD). The results demonstrate that compared to the NG group, the HG group exhibits significantly increased neurological deficit and larger infarct area. Pre-treatment with LBP significantly attenuates these hyperglycemia-aggravated neurological deficits and reduces the infarct area. Furthermore, LBP treatment elevates the cell viability of HT22 cells in the HG and OD groups. Additionally, LBP significantly alleviates the hyperglycemia-induced downregulation of β-catenin and p-GSK-3β expression both in vivo and in vitro. These results demonstrate that LBP alleviates hyperglycemia-aggravated cerebral I/R injury by upregulating the Wnt/β-catenin signaling pathway.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 10","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145284803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信